GlassScriptPhysician profile
Travis J Gabriel
NPI 1073965943
$3,582.32
in general payments reported to CMS, 2019-2025
23 companies · $712 in 2025
The $712 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $68.96 · 2021: $471 · 2022: $441 · 2023: $644 · 2024: $1,133 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,488.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $434.03 | 2019-2025 | Total30, Precision 1, Dailies Total1 |
| Abbvie INC. | $395.45 | 2022-2025 | |
| Allergan, INC. | $363.17 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $358.78 | 2022-2025 | Xiidra, Miebo, Infuse |
| Coopervision INC. | $256.17 | 2019-2025 | Misight Contact Lens, Myday Contact Lens |
| Regeneron Healthcare Solutions, INC. | $227.14 | 2022-2025 | Eylea Hd, Eylea |
| Lkc Technologies, INC. | $222.37 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $175.07 | 2019-2024 | Cequa |
| Biotissue Holdings INC. | $155.61 | 2024-2025 | |
| Astellas Pharma Global Development | $150.00 | 2024 | Izervay |
| Kala Pharmaceuticals, INC. | $142.77 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $129.38 | 2023-2024 | Syfovre |
| Johnson & Johnson Vision Care, INC. | $113.80 | 2019-2025 | Acuvue |
| Oyster Point Pharma, INC. | $100.34 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $95.61 | 2024-2025 | Xdemvy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $51.68 | 2022-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.02 | 2019-2021 | |
| Thea Pharma INC. | $47.82 | 2023 | Iyuzeh |
| Dompe US, INC. | $38.00 | 2022-2025 | Oxervate |
| Shire North American Group INC | $29.44 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.36 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.23 | 2023 | Flarex |
| Astellas Pharma US INC | $14.08 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Gabriel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.